An MRD test does not have a “normal range” the way a cholesterol panel or blood count does. MRD stands for measurable residual disease (previously called minimal residual disease), and the result tells you whether cancer cells can still be detected in your body after treatment. The ideal result is “MRD negative” or “undetectable,” meaning the test found no remaining cancer cells at whatever sensitivity level it was designed to reach. An “MRD positive” result means the test picked up residual cancer cells, and the report usually includes a number describing roughly how many. Understanding what that number means, why it matters, and where the test can mislead you requires knowing a few things about how these tests work and what your specific cancer type demands.
What MRD Negative and MRD Positive Actually Mean
When your doctor says your MRD result is “negative,” they mean that the laboratory’s test could not find cancer cells in the sample it examined. This is different from saying zero cancer cells exist anywhere in your body. Every MRD assay has a detection limit, and the result is always “negative down to a certain level.” A test with a sensitivity of one in ten thousand (written as 10⁻⁴) can spot one cancer cell among ten thousand normal cells. A test sensitive to one in a hundred thousand (10⁻⁵) or one in a million (10⁻⁶) can go deeper. The sensitivity your test achieved matters enormously, because a result called “negative” at 10⁻⁴ leaves far more room for hidden disease than a result called “negative” at 10⁻⁶.
An MRD-positive result, by contrast, means the lab found residual cancer cells and can usually quantify them. Your report might say something like “MRD positive at 10⁻³,” meaning roughly one cancer cell per thousand normal cells was detected. That number gives your oncologist a sense of how much disease remains and how quickly it might grow back. MRD has emerged as one of the strongest independent predictors of outcome in several blood cancers, often outweighing traditional risk factors like white blood cell count at diagnosis or the specific chromosome changes found in your cancer cells.
Why MRD Matters for Your Prognosis
Across multiple blood cancers, achieving MRD negativity is consistently tied to longer remissions and better survival. In acute lymphoblastic leukemia, MRD status after initial treatment has largely superseded older risk markers as the most powerful predictor of whether the disease will return.1PubMed Central. Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia In multiple myeloma, a meta-analysis found that patients who reached MRD negativity had roughly double the progression-free survival compared with those who remained MRD positive, with median times of about 54 months versus 26 months.2JAMA Oncology. Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis In patients with relapsed or refractory myeloma treated with newer T-cell redirecting therapies, MRD-negative patients had a median progression-free survival of 20 months compared with just 3 months for MRD-positive patients, and their overall survival was dramatically longer as well.3PubMed Central. Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T‐cell redirecting immunotherapy
In acute myeloid leukemia, a large study found that patients who still had detectable molecular mutations during complete remission had a relapse rate of about 55%, versus roughly 32% for those without detectable mutations. Overall survival at follow-up was about 42% versus 66%.4PubMed. Molecular Minimal Residual Disease in Acute Myeloid Leukemia The pattern is remarkably consistent: clearing MRD is one of the best signals that treatment is working deeply enough to keep disease at bay.
That said, MRD negativity is not a guarantee. Some patients who test MRD negative still relapse, and some who test MRD positive enjoy long remissions. The test captures a snapshot at one moment from one sample site, and cancer biology is not always cooperative with our measurements. Many patients achieve apparently complete remission on scans and standard tests yet retain residual disease that eventually drives relapse.5PubMed Central. Targeting minimal residual disease: a path to cure? This is precisely why MRD testing was developed: to look deeper than conventional imaging and blood work.
How MRD Is Measured
There is no single MRD test. Several technologies exist, each with different strengths, and which one you receive depends on your cancer type, what’s available at your treatment center, and what molecular markers your cancer happens to carry. The three most common approaches are flow cytometry, PCR-based methods, and next-generation sequencing.
Flow cytometry works by running your bone marrow or blood sample past lasers that identify cells by the proteins on their surfaces. By using panels of colored antibodies, the lab can separate cancer cells from normal cells based on unusual protein combinations that healthy cells don’t display. A standardized eight-color antibody panel developed by the EuroFlow consortium achieved sensitivity at or below 10⁻⁵ in B-cell acute lymphoblastic leukemia, successfully distinguishing malignant from normal precursor cells in 99% of patients studied.6PubMed Central. Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia In acute myeloid leukemia, five-color flow cytometry identified usable leukemia-associated markers in 94% of cases, with sensitivity reaching 10⁻⁴ to 10⁻⁵.7American Journal of Clinical Pathology. Incidence, Sensitivity, and Specificity of Leukemia-Associated Phenotypes in Acute Myeloid Leukemia Using Specific Five-Color Multiparameter Flow Cytometry Flow cytometry is fast and widely available, but it requires fresh samples and depends on how well the lab’s antibody panel matches the quirks of your specific leukemia.
PCR-based methods amplify specific DNA sequences associated with the cancer, making even tiny amounts detectable. Quantitative PCR (qPCR) has been a workhorse for MRD monitoring for decades, particularly in leukemias with known gene rearrangements or fusion genes. It can be extremely sensitive but has an important quirk: it sometimes produces “positive non-quantifiable” results, meaning the test detects something but at a level too low to measure precisely. These borderline signals are a clinical headache because they can trigger treatment changes that may not actually be needed.
Next-generation sequencing is the newest major platform for MRD detection. It reads millions of DNA fragments simultaneously, looking for cancer-specific rearrangements or mutations. In one study of leukemia patients after stem cell transplant, NGS was used to recheck borderline qPCR-positive results: only about 28% of those borderline positives were confirmed by the more specific NGS method.8PubMed Central. NGS-MRD negativity in post-HSCT ALL spares unnecessary therapeutic interventions triggered by borderline qPCR results without an increase in relapse risk This suggests NGS can help filter out false alarms that PCR alone might trigger. In acute myeloid leukemia, sequencing-based MRD detection added significant prognostic information beyond what flow cytometry alone provided.4PubMed. Molecular Minimal Residual Disease in Acute Myeloid Leukemia
Why the Same Result Can Mean Different Things in Different Cancers
MRD testing was developed primarily for blood cancers, where the disease lives in bone marrow and blood that are relatively easy to sample repeatedly. In acute lymphoblastic leukemia, the methods are mature enough that MRD status routinely guides treatment decisions. European LeukemiaNet working groups have published consensus recommendations for MRD testing in acute myeloid leukemia, though they acknowledge that methods still lack full standardization across laboratories, which makes comparing results between centers tricky.9PubMed Central. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party In chronic lymphocytic leukemia, achieving undetectable MRD during treatment with venetoclax-based combinations is now being used to decide how long patients should stay on therapy.10PubMed. Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease Results from MRD-guided trials show that tailoring treatment length to how deeply and quickly the disease clears is feasible and produces outcomes that rival or exceed older fixed-duration approaches.11PubMed. MRD-driven treatment strategies in CLL: Current practice, limitations, and emerging paradigms
In multiple myeloma, MRD testing is gaining ground rapidly. Sustained MRD negativity lasting six months or more has been linked to further improvements in progression-free survival beyond what a single negative test predicts.12PubMed Central. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE This means your doctor may want to see MRD remain undetectable over multiple time points before drawing firm conclusions about your outlook. A newer approach using mass spectrometry can detect the myeloma-specific protein (M-protein) from a blood draw rather than a bone marrow biopsy, making serial monitoring less invasive while achieving similar prognostic value to bone marrow-based methods.13PubMed. Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma
MRD in Solid Tumors Is a Different Game
When people hear “MRD testing” in the context of breast cancer, colon cancer, or lung cancer, the technology is different from the bone marrow-based approaches used in leukemia. Solid tumor MRD testing relies on liquid biopsy, specifically looking for circulating tumor DNA (ctDNA) shed by cancer cells into the bloodstream.14PubMed Central. Liquid Biopsy to Detect Minimal Residual Disease: Methodology and Impact A positive ctDNA result after surgery strongly suggests residual cancer; a negative result is reassuring but less definitively so than in blood cancers, because solid tumors don’t shed DNA into the blood as reliably.
In colorectal cancer, patients who tested ctDNA-positive four weeks after surgery had dramatically worse outcomes without chemotherapy. Those who received adjuvant chemotherapy when ctDNA-positive saw a large benefit, while the emerging question is whether ctDNA-negative patients can safely skip chemotherapy altogether.15Nature Medicine. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer A UK-based randomized trial is now testing exactly that: whether ctDNA-guided treatment decisions are as good as giving chemotherapy to everyone with high-risk disease, potentially sparing patients unnecessary toxicity.16PubMed Central. ctDNA guided adjuvant chemotherapy versus standard of care adjuvant chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer
In breast cancer, ctDNA detection during follow-up has shown a striking ability to predict relapse months before scans or symptoms appear. One study found a median lead time of nearly 11 months before clinical relapse, and ctDNA detection was associated with relapse across all breast cancer subtypes.17PubMed Central. Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer Another study reported that ctDNA was detected ahead of clinical relapse in 16 of 18 patients who eventually relapsed, with a median lead time of about 9 months and specificity of 100% among nonrelapsing patients.18Clinical Cancer Research. Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence These findings are exciting, but the key caveat is that ctDNA-based MRD testing in solid tumors is still being validated for clinical decision-making. Your oncologist may be able to order it, but in many situations the evidence for changing treatment based on the result is still catching up.
What Can Make Your MRD Result Wrong
False negatives and false positives both happen with MRD testing, and understanding the common pitfalls helps you have a more informed conversation with your doctor.
False negatives, where the test says MRD negative but disease is actually present, can occur for several reasons:
- Hemodilution: If the bone marrow sample gets diluted with blood during collection, the cancer cells become too sparse relative to normal cells for the test to detect them.19PubMed Central. Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma
- Patchy disease: Cancer cells may cluster in some areas of bone marrow but not others. A biopsy from a clear spot misses the disease lurking elsewhere.
- Low cell counts after chemotherapy: If treatment has hammered the marrow, the sample may simply not contain enough cells to give the test a fair chance at finding a rare cancer cell among them.20PubMed Central. False-Positive and False-Negative MRD Results in Children with Acute Lymphoblastic Leukemia: Navigating Between Scylla and Charybdis
- Extramedullary disease: In myeloma and some leukemias, cancer can grow outside the bone marrow entirely. A bone marrow test won’t find what isn’t there.
False positives are equally problematic and come from a different set of traps. In liquid biopsy-based testing for solid tumors, the biggest confounder is clonal hematopoiesis of indeterminate potential (CHIP). This is an age-related phenomenon where blood-forming cells accumulate mutations that look like cancer mutations but aren’t actually from a tumor. When defined by a commonly used threshold, CHIP mutations have been found in about 40% of people over 60. Some of these mutations occur in the same genes associated with solid tumors, including TP53, which accounted for 10% of all CHIP mutations in one large genomic study.21PubMed Central. Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA More advanced bioinformatics filtering is reducing CHIP-related false positives, but it remains a real limitation, especially for older patients.22PubMed Central. False-Positive Liquid Biopsy Assays Secondary to Overlapping Aberrant Methylation from Non-Cancer Disease States
Non-cancer conditions can also interfere. Autoimmune diseases, chronic infections, and even prior chemotherapy or radiation can alter DNA methylation patterns or create mutations in blood cells that mimic tumor signals. If you’ve had a liquid biopsy MRD test come back positive and the clinical picture doesn’t quite match, your oncologist should consider whether a confounding source could explain the result.
How MRD Results Guide Treatment Decisions
The way MRD results translate into clinical action varies by disease. In acute lymphoblastic leukemia, a positive MRD result after induction chemotherapy may prompt your team to intensify treatment or recommend a bone marrow transplant. In chronic lymphocytic leukemia, achieving undetectable MRD during venetoclax-based therapy can determine when it’s safe to stop treatment rather than continuing for a fixed duration.10PubMed. Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease This is a meaningful shift from older paradigms where patients took drugs for a preset length of time regardless of how deeply their disease responded.
In myeloma, one economic analysis found that using MRD testing to guide treatment decisions saved roughly €77,000 per patient over ten years compared with no MRD testing, mainly by identifying patients who could safely take a “drug holiday” rather than remaining on expensive continuous therapy.23PubMed Central. A Cost Impact Analysis of clonoSEQ® as a Valid and CE-Certified Minimal Residual Disease (MRD) Diagnostic Compared to No MRD Testing in Multiple Myeloma in Germany For patients, this means fewer side effects and less financial burden; for healthcare systems, it means better resource allocation.
In acute myeloid leukemia, MRD is being used alongside traditional risk factors to help decide whether a patient needs a transplant or can be managed with chemotherapy alone. The European LeukemiaNet consensus recognizes MRD as an important biomarker for prognosis, treatment monitoring, and assessing how well new drugs work in clinical trials.24PubMed Central. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party One challenge the field still faces: the lack of standardization across laboratories means MRD results from one institution aren’t always directly comparable to results from another.
Insurance Coverage Is Uneven
If you’re wondering whether your insurer will pay for MRD testing, the answer depends on where you live, what kind of cancer you have, and which test is being ordered. In the United States, a review of insurance policies found that about 65% of private payer policies that addressed MRD testing provided coverage for it, while all Medicare local coverage determinations that addressed circulating tumor DNA tests covered at least one indication.25PubMed Central. Private Payer and Medicare Coverage Policies for Use of Circulating Tumor DNA Tests in Cancer Diagnostics and Treatment Coverage was most common when the test was used for initial treatment selection, and less common for monitoring progression or detecting residual disease. If your oncologist recommends MRD testing and you’re concerned about coverage, asking the lab about pre-authorization and checking your plan’s specific policy is worth doing before the test is ordered.
The Anxiety Side of Repeated Testing
MRD monitoring often means repeated bone marrow biopsies or blood draws over months to years, and the emotional toll is real. “Scanxiety,” the dread that builds before getting test results, is well-documented among cancer patients. In one study, 79% of patients rated the results themselves as their greatest source of anxiety before a scan, and that figure rose to 87% after the scan was done.26PubMed Central. Scanxiety among Adults with Cancer: A Scoping Review to Guide Research and Interventions MRD testing carries the same psychological weight, arguably more so because the stakes feel binary: negative or positive, safe or at risk. If you find the waiting period before MRD results distressing, you’re in good company, and it’s worth raising with your care team. The anxiety is a recognized part of cancer survivorship, not a sign of weakness.
Where MRD Testing Is Headed
The technology is evolving rapidly. Single-cell sequencing methods are being developed that could allow the lab to analyze individual cancer cells rather than bulk populations, potentially catching clones that current methods miss.27PubMed Central. Advancing MRD Detection in Multiple Myeloma Technologies, Applications, and Future Perspectives Mass spectrometry-based blood tests for myeloma are already showing that bone marrow biopsies may not always be necessary for reliable MRD assessment.13PubMed. Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma In solid tumors, larger randomized trials are underway to determine whether ctDNA-guided treatment decisions actually improve survival and reduce unnecessary chemotherapy, rather than just predicting who will relapse.
The broader trajectory is toward making MRD testing less invasive, more standardized, and more directly tied to treatment decisions rather than being one data point among many. For now, MRD results are most actionable in blood cancers where the testing technology is mature and consensus guidelines exist. In solid tumors, the science is compelling but the clinical framework is still catching up. If you’ve received an MRD result and aren’t sure what it means for your specific situation, the most productive step is asking your oncologist three questions: what sensitivity level did the test reach, how does this result change my treatment plan, and when should the test be repeated.